Granules India Management

Management criteria checks 0/4

Granules India's CEO is Krishna Chigurupati, appointed in Jan 2022, has a tenure of 2.33 years. total yearly compensation is ₹353.56M, comprised of 5.1% salary and 94.9% bonuses, including company stock and options. directly owns 35.54% of the company’s shares, worth ₹36.42B. The average tenure of the management team and the board of directors is 1.4 years and 2.4 years respectively.

Key information

Krishna Chigurupati

Chief executive officer

₹353.6m

Total compensation

CEO salary percentage	5.1%
CEO tenure	2.3yrs
CEO ownership	35.5%
Management average tenure	1.4yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Krishna Chigurupati's remuneration changed compared to Granules India's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹4b
Sep 30 2023	n/a	n/a	₹4b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹354m	₹18m	₹5b
Dec 31 2022	n/a	n/a	₹5b
Sep 30 2022	n/a	n/a	₹5b
Jun 30 2022	n/a	n/a	₹4b
Mar 31 2022	₹272m	₹18m	₹4b
Dec 31 2021	n/a	n/a	₹4b
Sep 30 2021	n/a	n/a	₹5b
Jun 30 2021	n/a	n/a	₹6b
Mar 31 2021	₹419m	₹18m	₹5b
Dec 31 2020	n/a	n/a	₹5b
Sep 30 2020	n/a	n/a	₹4b
Jun 30 2020	n/a	n/a	₹4b
Mar 31 2020	n/a	n/a	₹3b
Dec 31 2019	n/a	n/a	₹3b
Sep 30 2019	n/a	n/a	₹3b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹150m	₹18m	₹2b
Dec 31 2018	n/a	n/a	₹2b
Sep 30 2018	n/a	n/a	₹2b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹112m	₹18m	₹1b

Compensation vs Market: Krishna's total compensation ($USD4.24M) is above average for companies of similar size in the Indian market ($USD433.43K).

Compensation vs Earnings: Krishna's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Krishna Chigurupati (69 yo)

2.3yrs

Tenure

₹353,560,000

Compensation

Dr. Krishna Prasad Chigurupati, B.Sc. had been Managing Director of Granules India Limited since September 1, 2009. He serves as Chairman of Granules India Limited and has been its Non-Independent Executiv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Krishna Chigurupati	Chairman & MD	2.3yrs	₹353.56m	35.54% ₹ 36.4b
Kandiraju Venkata Sita Rao	Joint MD	2.3yrs	₹94.56m	no data
Harsha Chigurupati	Executive Director	no data	₹35.36m	no data
Sanjay Kumar	President	1.3yrs	no data	no data
Mukesh Surana	Chief Financial Officer	1.3yrs	no data	no data
Sethu Sankaran	Senior Vice President of API Manufacturing & Operations	less than a year	no data	no data
P. Srinivas	Chief Technology Officer	1.4yrs	no data	no data
Chaitanya Tummala	Company Secretary & Compliance Officer	9.8yrs	₹7.89m	no data
Atul Dhavle	Chief Human Resources Officer	less than a year	no data	no data
Priyanka Chigurupati	Whole-Time Director	less than a year	₹9.65m	0.75% ₹ 769.0m
G. Prashanth	Senior VP & Head Corporate Quality	4.6yrs	no data	no data
Manikandan Ramalingam	Senior VP and Head Formulation R&D	no data	no data	no data

1.4yrs

Average Tenure

55yo

Average Age

Experienced Management: 532482's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Krishna Chigurupati	Chairman & MD	29.8yrs	₹353.56m	35.54% ₹ 36.4b
Kandiraju Venkata Sita Rao	Joint MD	2.3yrs	₹94.56m	no data
Harsha Chigurupati	Executive Director	13.8yrs	₹35.36m	no data
Priyanka Chigurupati	Whole-Time Director	less than a year	₹9.65m	0.75% ₹ 769.0m
Saumen Chakraborty	Additional Non-Executive Independent Director	2.4yrs	₹4.18m	no data
Sethurathnam Ravi	Non-Executive Independent Director	less than a year	no data	no data
Kapil Mehan	Independent Director	less than a year	no data	no data
Rajiv Kakodkar	Non-Executive Independent Director	less than a year	no data	no data
Arun Akinepally	Lead Independent Non-Executive Director	14.1yrs	₹4.72m	0.11% ₹ 117.5m
Uma Chigurupati	Non-Independent Executive Director	12yrs	₹35.36m	3.81% ₹ 3.9b
Kolli Rao	Non-Executive Non-Independent Director	11.3yrs	₹4.33m	1.21% ₹ 1.2b
Sucharita Palepu	Additional Non-Executive Independent Director	2.4yrs	₹3.85m	no data

2.4yrs

Average Tenure

64yo

Average Age

Experienced Board: 532482's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Granules India Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new directors

Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer

Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing

Granules India Limited, Annual General Meeting, Aug 10, 2023

Granules India Limited Announces Resignation of Sandip Neogi as Chief Financial Officer (Cfo)

Granules India Limited, Annual General Meeting, Jul 27, 2022

Recent updates

High number of new directors

Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer

Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing

Consensus EPS estimates fall by 14%

Third quarter 2024 earnings released: EPS: ₹5.18 (vs ₹5.11 in 3Q 2023)

Granules India Limited to Report Q3, 2024 Results on Jan 23, 2024

Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets

Price target increased by 8.1% to ₹375

Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹5.85 in 2Q 2023)

Granules India Limited to Report Q2, 2024 Results on Nov 09, 2023

Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules

Consensus EPS estimates fall by 18%

Granules India Limited Approves Final Dividend for the Fy 2022-23

Granules India Limited Receives US FDA Approval for the ANDA Files for Metoprolol Succinate ER Tablets Registered Office

Granules India Limited to Report Q1, 2024 Results on Aug 09, 2023

Upcoming dividend of ₹1.50 per share at 0.5% yield

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Granules India Limited Announces Approval for the Store Brand OTC Equivalent of Advil®? Dual Action Tablets Registered Office

Granules India Limited Receives ANDA Approval for Venlafaxine ER Capsules

Granules India Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2023 earnings: EPS misses analyst expectations

Granules India Limited to Report Q3, 2023 Results on Jan 24, 2023

Granules India Limited Announces Resignation of Sandip Neogi as Chief Financial Officer (Cfo)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Granules India Limited to Report Q2, 2023 Results on Oct 20, 2022

Granules India Limited Receives Approval for Abbreviated New Drug Application from US Food & Drug Administration

Price target increased to ₹338

Granules India Limited (BSE:532482) announces an Equity Buyback for 6,250,000 shares, representing 2.52% for INR 2,500 million.

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Granules India Limited to Report Q1, 2023 Results on Aug 09, 2022

Granules India Limited Approves Final Dividend for the Financial Year 2021-22

Upcoming dividend of ₹0.75 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Price target decreased to ₹319

Granules India Limited, Annual General Meeting, Jul 27, 2022

Consensus forecasts updated

Price target decreased to ₹330

Granules India Recommends Final Dividend for the Financial Year 2021-22

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Granules India Limited Declares Third Interim Dividend for the Financial Year 2021-22

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Insufficient new directors

Second quarter 2022 earnings released: EPS ₹3.26 (vs ₹6.60 in 2Q 2021)

Upcoming dividend of ₹0.25 per share

Price target decreased to ₹388

Insider recently sold ₹1.2m worth of stock

Upcoming dividend of ₹0.25 per share

Upcoming dividend of ₹0.75 per share

Full year 2021 earnings released: EPS ₹22.05 (vs ₹13.19 in FY 2020)

Insider recently sold ₹11m worth of stock

Non-Executive Non-Independent Director recently sold ₹50m worth of stock

Consensus forecasts updated

Full year 2021 earnings released: EPS ₹22.05 (vs ₹13.19 in FY 2020)

Granules India Limited Recommends Final Dividend for the Year Ended March 31, 2021

Granules India Limited Announces Approval of Potassium Chloride ER Capsules USP

Upcoming Dividend of ₹0.25 Per Share

Third quarter 2021 earnings released: EPS ₹5.92 (vs ₹2.52 in 3Q 2020)

Revenue beats expectations, earnings disappoint

New 90-day low: ₹340

Granules India Limited Announces USFDA Approval of Metformin Hydrochloride ER Tablets USP

Granules India Limited to Report Q3, 2021 Results on Jan 28, 2021

Insider recently sold ₹70m worth of stock

Insider recently sold ₹3.8m worth of stock

New 90-day low: ₹343